Goldman Sachs reinstated coverage of Esperion (ESPR) with a Neutral rating and $4 price target Post the label expansion, Nexletol and Nexlizet uptake has started to pick up but key opinion leader feedback remains mixed, the analyst tells investors in a research note. The firm says investor focus has likely returned to Esperion’s commercial prospects and fundamentals, which it views balanced at the current share price.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion initiated with an Overweight at Cantor Fitzgerald
- Esperion entered into licensing agreement with Neopharm Israel
- Esperion selloff continues following competitor data from NewAmsterdam
- Biotech Alert: Searches spiking for these stocks today
- Esperion announces new drug submissions in Canada for NEXLETOL